Frank Griesinger
@GriesingerFrank
Followers
90
Following
245
Media
15
Statuses
306
Impact of Multidisciplinary Cancer Conferences on Overall Survival: A Meta-Analysis
academic.oup.com
AbstractBackground. Multidisciplinary cancer conferences consist of regular meetings between diverse specialists working together to share clinical decisio
3
1
5
🚨Disappointing results!! @sanofi announces CARMEN-LC03 trial failed to improve PFS in previously treated pts with metastatic NSq NSCLC with high levels of CEACAM5 ⚒️The tusamitamab ravtansine clinical development program will be discontinued https://t.co/HsX5Tu41Qs
globenewswire.com
Sanofi announces end of program evaluating tusamitamab ravtansine after a 2L NSCLC Phase 3 trial did not meet a primary endpoint CARMEN-LC03 trial...
3
8
18
What a disappointment!!!Complexity of ADCs mechanisms of action and need to review selection of patients with fresh tumor biopsy ?
🚨Disappointing results!! @sanofi announces CARMEN-LC03 trial failed to improve PFS in previously treated pts with metastatic NSq NSCLC with high levels of CEACAM5 ⚒️The tusamitamab ravtansine clinical development program will be discontinued https://t.co/HsX5Tu41Qs
2
6
11
EXCLAIM2 trial: mobicertinib vs CT in 1st line EGFRex20ins 🫁NSCLC is ⛔️. Amivantamab + CT potential🦋new SoC in this population. However our hopes in new EGFRex20ins TKI with promising efficacy and better toxicity profile, and perhaps better icRR 🧠➡️relevant point!! #ESMOAsia23
3
13
51
Cuando no estás enfermo, la necesidad no parece tan urgente. En curva de la derecha la supervivencia global de acuerdo a la aprobación EMA: 85% vivos a 3 años frente a situación en España: 66% vivos en 3 años. Por favor que nuestros "expertos" expliquen qué no entienden.
8
36
86
FLAURA2 Editorial @NEJM from Drs. Yi-long Wu and Qing Zhou. Do the PFS benefits outweigh the toxicity and need for infusions every 3 weeks? A survey by the Chinese Thoracic Oncology Group of 363 pts showed 73% chose monotherapy even with 9m PFS benefit (79% who had prior chemo).
4
29
84
FLAURA2 now @NEJM. Phase III trial of first-line osimertinib alone or with chemotherapy for #EGFR NSCLC (n=557). Adding chemotherapy significantly improved PFS (HR 0.62) and mDOR (15.3m vs 24m), but at the cost of added toxicity (and q3w infusions). https://t.co/FbCxfqJwkF
nejm.org
Osimertinib is a third-generation epidermal growth factor receptor–tyrosine kinase inhibitor (EGFR-TKI) that is selective for EGFR-TKI–sensitizing and EGFR T790M resistance mutations. Evidence sugg...
2
27
63
💥Hot off the press👉 Pleased to share our paper 👉Association between treatment and improvements in overall survival of patients with advanced/metastatic non–small cell lung cancer since 2011: A study in the United States, Canada, & Germany using retrospective real-world
2
7
24
Dr. Tanasombatkul, a 29 y/o doctor with stage 4 #lungcancer shares that he does not have much time left. He wants others to know “Everyone can get this bc the world has become abnormal, with air & water pollution and various forms of radiation and our genes are ready to mutate"
Moral support has poured in for Dr. Krittai Tanasombatkul, with his hashtag “Don’t give up” (#สู้ดิวะ) top trending on X today, after he updated his condition as he suffers with his terminal lung cancer, saying he may succumb to the disease in the middle of December. Read more:
1
6
20
Moral support has poured in for Dr. Krittai Tanasombatkul, with his hashtag “Don’t give up” (#สู้ดิวะ) top trending on X today, after he updated his condition as he suffers with his terminal lung cancer, saying he may succumb to the disease in the middle of December. Read more:
1
47
62
Estudios de inmunoterapia en cáncer publicados en el NEJM.
3
14
52
RT @high5md: It's a wrap! #ESMO23 has come to an end. A great conference, with practice changing and exciting new data on #breastcancer, #l…
0
2
0
#ESMO23 Presidential 1 THE LungCancer story ♥️ - PAPILLON ✅ - ALINA ✅ - LIBRETTO 431 ✅ - CheckMate77L ✅ What else?! 🔥
3
25
139
🤔FLAURA-2 CNS results #ESMO23 Osi is supposed to have good brain penetrance. Addition of chemo increases brain RR in EGFR pts 🙋Is it because it increases brain delivery of osi or it targets osi resistant / persister cells in the brain ? 👍Anyway, impactful data. @OncoAlert
0
32
75
Impressive waterfall plot for #NSCLC KRASG12C PDL1 > 50% treated in first line by pembrolizumab + Adagrasib. RR 63%. Manageable liver toxicity. #ESMO23 @OncoAlert
0
33
89
Disappointing 🥲🥲🥲🥲
Tropion Lung01 - phase 3 trial of DatoDXD vs docetaxel in pretreated NSCLC. PFS 4.4m DatoDXD vs. 3.7m docetaxel. Stomatitis a concern with datodxd. Unfortunately not yet the major advance we had been hoping to see. #lcsm
2
1
6
ESMO LBAs! -ALINA adj alectinib HR DFS .24 -PAPILLON 1L Ct-amivantamab vs Ct in EGFR Ex20 HR PFS .40 -LIBRETTO-431 1L selperca vs Ct-IO in RET+ HR PFS .46 -CM77T periop nivo HR EFS .58 -MARIPOSA 1L ami-laz vs osi in EGFRmut HR PFS .70 -TROPION 2L+ Dato-DXd vs docetaxel HR PFS .75
1
45
119
Amazing news. Looking forward to #ESMO23. I suspect this strategy will become widely used.
💥Merck Announces Pivotal KEYNOTE-671 Trial Meets Dual Primary Endpoint of Overall Survival (OS) in Resectable Stage II, IIIA or IIIB Non-Small Cell Lung Cancer (NSCLC)
1
3
12
Press release: phase III MARIPOSA study meets its primary endpoints. First line amivantamab plus lazertinib superior to osimertinib in #EGFR mutant NSCLC (del19, L858R) with significant and "meaningful" improvement in PFS (and OS trend). Await #ESMO23! https://t.co/AOyYxawsJ9
prnewswire.com
/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced positive topline results from the Phase 3 MARIPOSA study evaluating...
4
70
210